Charlotte's Web Holdings Inc (CWBHF)

[DarthYoda]

Walmart is now selling CW's Mushroom Gummies and CW is now selling THC Gummies...
https://www.walmart.com/brand/charlottesweb/10034669
https://www.charlottesweb.com/collections/cbd-gummies/products/rest-relax
https://www.charlottesweb.com/collections/cbd-gummies/products/relieve-ease
https://www.charlottesweb.com/collections/cbd-gummies/products/focus-flow

[DarthYoda]

On page 11 of this USDA Hemp Report you can see what they say is the average U.S. price per pound for Cannabinoid Hemp Flower of $19.10. You can also see on that same page that they have the price per pound in each state ranging from $2.01 per pound in Kentucky to $1042.00 per pound in New Jersey. Their numbers are nonsense. In the second link you can clearly see the current price of CBD Rich Hemp flowers(small nugs) from a wholesaler in Oregon is $149.00 per half pound, or about $300 per pound. In the third link, you can see from the same wholesaler that the price of full sized CBD Rich Hemp Flowers is $40 per ounce, or about $640 per pound...
https://www.nass.usda.gov/Publications/Todays_Reports/reports/hempan25.pdf
https://oregon-hempflower.com/products/early-remedy-cbd-hemp-flower-smalls?variant=46733581320411
https://oregon-hempflower.com/products/sour-chem-cbd-hemp-flower-full-term?variant=46586105004251

[DarthYoda]

Interesting...there is no way USDA's numbers are correct...no one would ever sell a pound of Hemp cannabinoid flower for $19.10...
"Hemp: USDA Report Has Methodological and Data Errors, Paints Inaccurate Picture of U.S. Hemp Market":
May 13, 2025

"How does $445 million of output produce a cannabinoid market of $28.4 billion? Simply put, it does not."

The average price per pound the USDA uses to determine the value of this year’s crop for flower was $19.10 per pound. In addition, the yield per acre of a hemp cannabinoid farm is estimated to be roughly 1,700 pounds. W.E. models 2,000 plants per acre, so this is less than a pound per plant in terms of yield. The total yield according to the report was roughly 20,784,000 pounds or slightly over $400 million in value.

This does not add up. Who do you trust: USDA or the industry?

Based on data from Hemp Benchmarks, the average price per pound of hemp cannabinoid flower has consistently been in excess of $310. In December 2024, the price per pound topped $374. If this is the case, then the value of the hemp flower crop would range from $6.5 billion to $7.8 billion. This is more in line with a cannabinoid end-product market that is valued at more than $28 billion. So either the USDA is wrong or Hemp Benchmarks is. They cannot both be true. W.E. feels that Hemp Benchmark’s data is closer to the actual market price of the crop.
Source: https://www.hempbenchmarks.com/hemp-market-insider/april-2025-hemp-spot-price-index-report/
Conclusion:
The USDA report is actually doing a disservice to the hemp industry. The methodological errors and the widespread distribution of this report is conveying inaccurate data to the market. This is impacting the investment opportunities and development of the infrastructure. The USDA has tried to use the same old formulas used to track soy, corn and wheat and apply them to hemp. This simply does not work. The inaccurate data is impacting the growth of the hemp market and shows that even after five years since the passage of the 2018 Farm Act, the USDA still does not collect and publish good data about what could be America’s fourth largest crop.

https://letstalkhemp.com/hemp-usda-report-has-methodological-and-data-errors-paints-inaccurate-picture-of-u-s-hemp-market/

[Fangster]

Have to agree.  CW presented a much improved picture for Q1 but much to do still. 
MLB should have been more useful but is what it is and time to put these resources to work elsewhere.  
Whole Foods is a great development with its higher end consumer base.  However, they're not ready to bring CBD into their sales offering but I believe this will change at some point.  
I thought internal manufacturing was fully transitioned in at this point but this is a further positive at this point.  And, appears new offerings are being cued up.  
The sleeper is the AJNA JV.  The June conference with CW and AJNA will definitely get more eyes on this.  An out year catalyst for sure but a massive one nonetheless. 
There's been a lot of trolling on the new exec team which I felt was way overdone.  IMO, the exec team has this going in the right direction and gets positive grades. 

[DarthYoda]

A few quick thoughts on Q1 report. First, I am so glad they concluded the MLB deal. MLB got way overpaid to not do much for CW in return. By doing that, CW will be saving $18mil going forward. Second, Q1 is always their lightest quarter, but Q1 this year is higher than Q1 last year, so that's good. Third, the mentioned upcoming Whole Foods rollout in 400 stores is a big positive. Fourth, they have an upcoming Executive Panel at the Chicago Benzinga Cannabis Conference on June 9th...links below...
Q1 Press Release
https://www.otcmarkets.com/filing-file/2ef130f2-b7eb-4128-99de-f298522415f6/contents
Q1 MD&A
https://www.otcmarkets.com/filing-file/dab13790-c4ce-4bab-b4de-19d48525f033/contents
Q1 Report
https://www.otcmarkets.com/filing-file/3b5276cc-b3c3-4282-809f-cb134ad783b1/contents

[DarthYoda]

This new article is about a possible new third endocannabinoid receptor(CB3) which is currently called GPR55. It explains how THC without CBD could possibly exacerbate certain cancers through interacting with GPR55 while simultaneously combatting that same cancer through other pathways. It also explains how CBD interacts with GPR55 to produce anti-cancer effects with and without THC. The whole article is good info. Below is just a portion of it...
"GPR55: A New Cannabinoid Receptor with Big Potential?"
May 10, 2025

"Agonism vs. Antagonism at GPR55: A Case in Point"
One of the clearest examples of how agonism and antagonism at a receptor can produce opposite clinical effects is seen in triple-negative breast cancer (TTT-). GPR55 is overexpressed in certain aggressive breast cancer subtypes, and its activation has been shown to promote tumor cell migration, invasion, and metastasis.

In this context, THC, acting as a GPR55 agonist, may unintentionally contribute to cancer progression. Although studies used LPI (the endogenous ligand) to activate GPR55 in TTT- models (C. Andradas et al. 2016), the mechanistic parallels raise concerns about THC’s potential to fuel similar pathways.

In contrast, CBD, acting as a GPR55 antagonist, may counter these effects by blocking the receptor. Preclinical research supports CBD’s ability to inhibit proliferation, migration, and angiogenesis in aggressive cancer models—likely, at least in part, due to this antagonistic action at GPR55.

Clinical takeaway:
In GPR55-expressing tumors like TTT-, THC-rich formulations may pose a risk due to receptor activation.
CBD-dominant or balanced CBD:THC formulations may offer a safer therapeutic approach, particularly if GPR55 modulation is a concern.
These contrasting effects underscore the importance of personalized cannabinoid care guided by cancer type, receptor profile, and formulation precision.
Importantly, THC still exerts anticancer effects through other mechanisms, including CB1, CB2, TRPV1, and pro-apoptotic pathways. By co-administering CBD or other GPR55 antagonists, clinicians may preserve THC’s therapeutic benefits while minimizing its potential to promote metastasis via GPR55.

Other Therapeutic Implications of GPR55 Modulation
While the oncology context demands caution, GPR55 also plays a role in several neurological and inflammatory processes, where antagonism by CBD or agonism by THC may be beneficial:

-Epilepsy and Neuroprotection: CBD’s inhibition of GPR55 reduces intracellular calcium release and excitotoxicity—key drivers of seizure activity (Kaplan et al., 2017).
-Fragile X Syndrome: CBD improved behavior and memory in a Fragile X model via hippocampal GPR55 modulation (Manduca et al., 2024).
-Excitotoxicity and Glutamate Modulation: THC’s agonism at GPR55 activates intracellular Ca2+ release in neurons, altering excitability and promoting glutamate release, making GPR55 antagonists a potential novel treatment approach for excitotoxicity (J. E. Lauckner et al., 2008).

These applications suggest that CBD’s antagonistic action at GPR55 may hold broad therapeutic value beyond oncology, particularly in neurological and neurodevelopmental disorders—and that both CBD antagonism and THC agonism at this receptor can, in the right context, be therapeutically harnessed, depending on the condition and desired clinical effect.

https://cannakeys.com/gpr55-a-new-cannabinoid-receptor-with-big-potential/

[DarthYoda]

Here are three more brand new papers on the Anti-Cancer effects of three different Cannabinoids, CBG, CBN, and of course CBD...
Anti-Cancer effects of CBG..."Evaluating Cannabigerol as a Therapeutic Agent in Non-Alcoholic Fatty Liver Disease":
May 05, 2025

We found that CBG is able to inhibit tumor growth and induce changes in lipid handling within the liver.

https://digscholarship.unco.edu/theses/341/
Anti-Cancer effects of CBN..."Cannabinol improves exemestane efficacy in estrogen receptor-positive breast cancer models: a comparative study with cannabidiol":
7 May 2025

...only the combination of CBN with Exe induced a significant beneficial impact on viability and growth of ER+ breast cancer cells and spheroids.

In conclusion, this study strengthens the hypothesis that cannabinoids are important anti-cancer agents with attractive co-adjuvant properties.

https://www.sciencedirect.com/science/article/pii/S0014299925004662
More Anti-Cancer effects of CBD..."Cannabidiol-loaded-injectable depot formulation for the treatment of triple-negative breast cancer: design, development, in-vitro and in-ovo evaluation of its anticancer activity":
9 May 2025

Finally, this formulation reduced the growth of MDA-MB-231-derived tumors developed in the chorioallantoic membrane (CAM) model. The single administration of 10-CB-ISFI exhibited a similar antitumor efficacy to the daily administration of CBD in solution (˜60% tumor growth inhibition). Therefore, the injectable depot formulation of CBD developed in this work showed a promising utility in TNBC treatment.

https://www.sciencedirect.com/science/article/pii/S0378517325005472

[DarthYoda]

Several articles and more new studies have been coming out recently showing the anti-cancer and anti-tumor properties of cannabis in general and CBD in particular...Does the FDA care to investigate? It's just CANCER. Why should HEALTH and HUMAN SERVICES care about that?...
"Why cannabis holds real promise as a treatment for cancer, according to a sweeping new study":
May 7, 2025

The study reviewed more than 10,000 published papers on medical cannabis. That makes it the most comprehensive analysis ever conducted on the topic, according to a recent story in The Guardian.

https://www.kunc.org/podcast/inthenoco/2025-05-07/why-cannabis-holds-real-promise-as-a-treatment-for-cancer-according-to-a-sweeping-new-study
Here is the Guardian article mentioned..."Medical cannabis shows potential to fight cancer, largest-ever study finds":
18 Apr 2025

Castle says his team hoped to find “a moderate consensus” about cannabis’s potential as a cancer treatment, and expected the “best case scenario” to be something like 55% of studies showing that medical cannabis improved cancer outcomes.

“It wasn’t 55-45, it was 75-25,” he said.

The study overwhelmingly supported cannabis as a treatment for cancer-related inflammation, appetite loss and nausea. Perhaps more surprisingly, it also showed that cannabis has the potential to fight cancer cells themselves, by killing them and stopping their spread.

“That’s a shocking degree of consensus in public health research, and certainly more than we were anticipating for a topic as controversial as medical cannabis,” Castle said.

https://www.theguardian.com/us-news/2025/apr/18/medical-cannabis-cancer-study
Here is the study cited..."Meta-analysis of medical cannabis outcomes and associations with cancer":
14 April 2025
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1490621/full
And here is another unrelated brand new study showing more anti-cancer effects of CBD. As has been shown in the numerous other studies I have posted over the years, CBD also has a particularly synergistic anti-cancer effect when combined with certain chemotherapy drugs..."Cannabidiol potentiates p53-driven autophagic cell death in non-small cell lung cancer(NSCLC) following DNA damage: a novel synergistic approach beyond canonical pathways":
Published: 01 May 2025

Our results revealed that, among various tested chemotherapeutic drugs, etoposide showed the most significant reduction in NSCLC cell viability when combined with CBD.

Interestingly, our analysis revealed that this combination therapy did not rely on traditional cannabinoid receptors or transient receptor potential cation channels, indicating that CBD exerts its anticancer effects through novel, noncanonical mechanisms. The findings suggest that the combination of CBD with etoposide could represent a groundbreaking approach to NSCLC treatment, particularly in cases where conventional therapies fail. By inducing autophagic cell death and inhibiting oncogenic pathways, this therapeutic strategy offers a promising new avenue for enhancing treatment efficacy in NSCLC, especially in tumors with p53 function.

https://www.nature.com/articles/s12276-025-01444-x

[DarthYoda]

60 days left for FDA to respond to this citizen petition fixing the IND Preclusion..."by July"...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175884299

[DarthYoda]

Congress & FDA & HHS & President=TRASH..."Four months into session, no bills have been introduced in Congress to authorize FDA to establish a regulatory pathway for the lawful use of hemp ingredients in products other than drugs or propose some other solution to the federal conundrum present since lawmakers in 2018 de-scheduled hemp."
29 Apr 2025
https://insights.citeline.com/hbw-insight/wellness/policy-and-regulation/legislation/digital-services-deliver-hemp-states-deliver-regulation-with-congress-yet-to-act-3YY3FHEXS5A2ZJAJNFJTT7LWAI/

[DarthYoda]

Three different CBD+Cancer papers were published on April 21st...
"CBD promotes antitumor activity by modulating tumor immune microenvironment in HPV associated Head and Neck Squamous Cell Carcinoma":
21 Apr 2025

Conclusions: CBD inhibits tumor cell proliferation in HPV-positive HNSCC by activating the MAPK pathway. It also enhances anti-tumor activity by modulating the tumor immune microenvironment, promoting co-localization of p38 MAPK-activated CD4+ and CD8+ T cells.

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1528520/abstract
"Exosomal formulation of cannabidiol (CBD) inhibits lung cancer proliferation and enhances uptake and tumor targeting":
April 21 2025

Overall, tumor-targeted exosomal formulations significantly enhance CBD’s bioavailability, tumor accumulation, and therapeutic efficacy. Combined with its ability to overcome chemotherapy resistance, these findings highlight the promise of CBD-loaded exosomes as a novel therapeutic against lung cancer.

https://aacrjournals.org/cancerres/article/85/8_Supplement_1/1788/756423
"Exploring the apoptosis-inducing potential of Cannabis sativa and cannabidiol in pancreatic cancer in vitro":
April 21 2025

In conclusion, both crude and CBD have apoptosis-inducing potential in pancreatic cancer cells.

https://aacrjournals.org/cancerres/article/85/8_Supplement_1/1388/756175

[DarthYoda]

"CBD Provides ‘Meaningful Benefits’ For Young Autism Patients, New Study Shows":
April 22, 2025
https://www.marijuanamoment.net/cbd-provides-meaningful-benefits-for-young-autism-patients-new-study-shows/
European Psychiatric Association Press Release..."Cannabidiol Therapy Could Reduce Symptoms In Autistic Children And Teenagers":
April 8, 2025
https://www.europsy.net/app/uploads/2025/04/Cannabidiol-Therapy-Could-Reduce-Symptoms-in-Autistic-Children-and-Teenagers.pdf
Ajna
https://ajnabiosciences.com/
Ajna Investor Deck
https://ajnabiosciences.com/wp-content/uploads/2025/02/Investor_Deck_2025_Public_PDF_web.pdf
DeFloria
https://defloria.bio/
DeFloria Investor Deck
https://foundersuite.com/public_pitch_decks/0b0d6e7a-bfa5-4f27-a77c-9bdfb57a673b
CWBHF
https://www.charlottesweb.com/
Charlotte's Web Investor Deck
https://s22.q4cdn.com/636117063/files/doc_downloads/factsheet/2025/CW-Factsheet_2025.pdf
"Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment":
February 24, 2025

It is exciting to see AJA001 advance through the botanical drug pathway following the guidance established by the FDA," stated Jinhui Dou, Ph.D., former FDA expert pharmacologist and botanical review team lead. "As the first orally ingested botanical drug designed to meet cGMP and quality standards, AJA001 is setting the bar for future pharmaceuticals in this class."

https://investors.charlottesweb.com/press-releases/press-release-details/2025/Charlottes-Web-Announces-DeFloria-to-enter-Phase-2-FDA-Clinical-Trial-for-Autism-Spectrum-Disorder-Treatment/default.aspx
"What is a Botanical Drug?":

To date, four botanical products have fulfilled the Botanical Guidance definition of a botanical drug product.

https://www.fda.gov/about-fda/cder-offices-and-divisions/what-botanical-drug
"Kennedy says HHS will know cause of 'autism epidemic' by September":
April 11, 2025
https://www.msn.com/en-us/health/other/kennedy-says-hhs-will-know-cause-of-autism-epidemic-by-september/ar-AA1CH5ai
Whether Botanical Drug or Dietary Supplement, CWBHF is prepared for and engaged in both pathways...
"Industry thought leaders discussed the prospect of Robert F. Kennedy, Jr. at the helm of HHS and Dr. Marty Makary in charge of FDA."
January 6, 2025

When asked about where he’d like to see decisive action, Mister said he’d like clarity on the drug preclusion provision of DSHEA. This provision precludes any ingredient from being marketed as a dietary supplement if ever authorized for research as an investigative new drug. FDA promised that they’re going to answer our citizen petition by July...

https://www.nutraceuticalsworld.com/exclusives/how-will-trump-nominations-impact-the-dietary-supplement-industry/
Here is the original citizen petition...
"CRN Petitions FDA to Change Course on ‘Drug Preclusion’":
May 10, 2023
https://www.nutraceuticalsworld.com/breaking-news/crn-requests-fda-to-change-course-on-drug-preclusion/
https://www.crnusa.org/sites/default/files/pdfs/comments-pdfs/CRN-CitizenPetition-FDA-DrugPreclusion050923.pdf

[DarthYoda]

Here are three different topics...

First, I see the CWBHF/Ajna/Defloria Youtube video link I posted last month isn't playing correctly, so here it is again. Maybe this link will work better...

Second, a new bipartisan Federal bill has been filed to end Federal prohibition of cannabis in States where it's legal...
"Bipartisan Congressional Lawmakers File Bill To End Federal Marijuana Prohibition In Legal States In Line With Trump’s Stance":
April 17, 2025

The legislation would amend the Controlled Substances Act (CSA) in a way that would prohibit federal criminalization of people acting in compliance with state cannabis programs, as well as those operated by Indian tribes.

https://www.marijuanamoment.net/bipartisan-congressional-lawmakers-file-bill-to-end-federal-marijuana-prohibition-in-legal-states-in-line-with-trumps-stance/
"Strengthening the Tenth Amendment Through Entrusting States (STATES) 2.0 Act":
https://www.documentcloud.org/documents/25900132-states-act-marijuana/

Third, I came across a CWBHF article and video "Charlotte’s Web charts new territory, expands into functional mushrooms":
24-Mar-2025
https://www.nutraingredients-usa.com/Article/2025/03/24/charlottes-web-expands-into-functional-mushrooms/

[MaxwellE]

This piece of garbage is just about done, soon to be .05, the .04, then .03, then .02, then .01, then adios. Can't happen soon enough...M

[DarthYoda]

A bunch of other different stuff below...

Charlotte's Web new 2025 Fact Sheet...
https://s22.q4cdn.com/636117063/files/doc_downloads/factsheet/2025/CW-Factsheet_2025.pdf

"Kennedy says HHS will know cause of 'autism epidemic' by September":
4/11/2025

After Kennedy's remarks, Trump said that autism could be caused by "something artificial" and "maybe it's a shot."
"There will be no bigger news conference than that...," Trump said. "If you can come up with that answer where you stop taking something, you stop eating something, or maybe it's a shot. But something's causing it."

https://www.msn.com/en-us/health/other/kennedy-says-hhs-will-know-cause-of-autism-epidemic-by-september/ar-AA1CH5ai

Maybe RFK and Dr. Makary can fast track this...
"Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment":
February 24, 2025
https://investors.charlottesweb.com/press-releases/press-release-details/2025/Charlottes-Web-Announces-DeFloria-to-enter-Phase-2-FDA-Clinical-Trial-for-Autism-Spectrum-Disorder-Treatment/default.aspx

It was so funny and so sad to hear the low IQ congressman, Pete Sessions, bring up Elton John's anti-cannabis nonsense in that congressional hearing when Elton John is a self admitted lifelong COCAINE ADDICT and ALCOHOLIC...
"Elton John's cocaine addiction and 20-year drug battle that nearly killed him":
https://www.mirror.co.uk/3am/celebrity-news/elton-johns-cocaine-addiction-20-27319720
"Elton John ‘drank a bottle of whisky a day’ when battle with alcoholism was at its worst":
https://metro.co.uk/2019/11/19/elton-john-drank-a-bottle-of-whisky-a-day-when-battle-with-alcoholism-was-at-its-worst-11178520/
The same super dumb and super dishonest congressman said he thought they were legalizing hemp in the 2018 Farm Bill "for rope". What an absolute lying evil loser idiot. The 2018 Farm Bill had an entire passage dedicated to the legalization of hemp derived Cannabinoids, which explicitly included, and still includes, hemp derived THC. By his own admission, he is way too stupid and evil to have the job he has. He should immediately be removed from office by any means necessary. All of these government people, on both sides of the aisle, are an embarrassment to our country.

[DarthYoda]

Lots of different stuff below...
"Restoring Trust in FDA: Rooting Out Illicit Products":

https://www.marijuanamoment.net/watch-live-hemp-industry-expert-testifies-before-congressional-committee-on-fda-inaction-around-cbd-and-intoxicating-cannabinoid-products/

"Charlotte's Web Holdings, Inc. (the "Issuer") Notice of Meeting and Record Date":
Annual General Meeting
Record Date for Voting (if applicable): April 15, 2025
Beneficial Ownership Determination Date: April 15, 2025
Record Date for Notice of Meeting: June 12, 2025
https://www.otcmarkets.com/filing-file/09a7cb3c-e998-4157-8892-3b89959fc9ea/contents

"King Charles turns to cannabis to try and gain a few more months to live":
03/17/2025

"He has always been a champion of homeopathic medicines and cures and sees there is no danger in trying the cannabis route. He's read all the studies around its benefits and is giving it a go."

https://www.marca.com/en/lifestyle/uk-news/2025/03/17/67d8610622601db45e8b45a2.html

"Breakthrough Study: CBD Calms Autism Symptoms and Improves Social Skills Without Side Effects":
April 8, 2025

Study Overview and Methodology
The meta-analysis included randomized, placebo-controlled trials on the efficacy or safety of CBD cannabis extracts in children and adolescents with ASD. Three studies were used in total with 276 participants with a mean age of 10.5, ranging in age from 5 to 21. The dosage of CBD cannabis extract started at 1 mg/kg per day and was titrated up to 10 mg/kg.

Key findings from the study include:
-CBD cannabis extract use shows moderate improvements in social responsiveness and small yet notable reductions in disruptive behaviors and anxiety
-CBD cannabis extract significantly enhanced social responsiveness, reduced disruptive behavior, and alleviated anxiety while also improving sleep quality
-The use of CBD cannabis extract has a favorable safety profile as it did not increase adverse events compared to placebo
-There were no significant differences between adverse events in CBD cannabis extract versus placebo

https://scitechdaily.com/breakthrough-study-cbd-calms-autism-symptoms-and-improves-social-skills-without-side-effects/

[DarthYoda]

"Congressional Committee Invites Hemp Industry Expert To Testify At Hearing On How FDA ‘Failed’ To Regulate Products":
April 4, 2025
https://www.marijuanamoment.net/congressional-committee-invites-hemp-industry-expert-to-testify-at-hearing-on-how-fda-failed-to-regulate-products/
"Hearing: “Restoring Trust in FDA: Rooting Out Illicit Products”:
Wednesday, April 9, 2025 (10:00 AM)
https://docs.house.gov/Committee/Calendar/ByEvent.aspx?EventID=118131

BACKGROUND:
The U.S. Food and Drug Administration (FDA) failed to approve products and take
necessary enforcement actions resulting in a flood of illicit and counterfeit products
entering the country. Entities controlled or affiliated with the Chinese Communist
Party are the primary manufacturers of these products.

https://docs.house.gov/meetings/GO/GO00/20250409/118131/HHRG-119-GO00-20250409-SD002.pdf
https://docs.house.gov/meetings/GO/GO00/20250409/118131/HHRG-119-GO00-20250409-SD001.pdf

[ap17]

LMFAO, Called for .10 and missed by .02, went to .08....OUCH told you don't marry a POS like this stock. .05 is a sure thing and that may be generous.

[Fangster]

Okay, should we follow your words with the same level of trust as your CVSI calls over the years?  🤣🤣🤣🤣

[ap17]

.05 coming here next. mark it!

[DarthYoda]

https://www.marijuanamoment.net/an-ointment-with-the-marijuana-components-cbd-and-cbg-can-effectively-treat-symptoms-of-eczema-study-shows/

[DarthYoda]

"Makary and Bhattacharya Confirmed to Head FDA, NIH":
3/27/2025
https://www.tctmd.com/news/makary-and-bhattacharya-confirmed-head-fda-nih
"RFK Jr. makes sweeping cuts in federal health programs, including CDC, FDA":
3/27/2025
https://www.msn.com/en-us/health/other/rfk-jr-makes-sweeping-cuts-in-federal-health-programs-including-cdc-fda/ar-AA1BMK3F

[DarthYoda]

"CBD-Rich Cannabis Offers ‘Potential Benefits’ For People With Autism Spectrum Disorder, Scientific Review Finds":
March 26, 2025
https://www.marijuanamoment.net/cbd-rich-cannabis-offers-potential-benefits-for-people-with-autism-spectrum-disorder-scientific-review-finds/
Here is the actual study...
"Efficacy and Safety of Cannabinoids for Autism Spectrum Disorder: An Updated Systematic Review":
Published: March 17, 2025 Peer-Reviewed
https://www.cureus.com/articles/347254-efficacy-and-safety-of-cannabinoids-for-autism-spectrum-disorder-an-updated-systematic-review#!/

[Wolf-man jack]

[

[DarthYoda]

"PA Supreme Court Approves OTC Supplements & CBD Oil for Workers’ Compensation":
March 20, 2025

This is a game changing decision requiring insurance carriers, third-party administrators and self-insured employers to pay for a broad array of non-prescription items including over-the-counter medications, dietary supplements, non-FDA approved analgesics, and CBD Oil.

https://www.jdsupra.com/legalnews/pa-supreme-court-approves-otc-8192541/

[Wolf-man jack]

Fourth Quarter 2024 Financial Review

Consolidated net revenue for the fourth quarter ended December 31, 2024, was $12.7 million, compared to $15.9 million in the fourth quarter of 2023. Revenue increased modestly on a quarter-over-quarter basis versus Q3 2024 revenue of $12.6 million.

Quarterly revenue trend for 2024:


Q1
Q2
Q3
Q4
U.S. $ millions
2024
2024
2024
2024
Total revenue
$ 12.1
$ 12.3
$ 12.6
$ 12.7





In the fourth quarter, some retailers were negatively impacted by state regulations restricting the sale of certain CBD products, despite meeting federal requirements. However, e-commerce revenue increased quarter-over-quarter following the launch of the Company's new e-commerce platform.

Gross Profit in Q4 2024 was $5.1 million, or 40.2% of revenue, compared to Gross Profit of $8.9 million, or 56.0% of revenue, in Q4 2023. The reduction in gross margin reflected holiday promotional investments, temporary shipping inefficiencies, and reduced fixed cost absorption on lower-than-expected revenue. The Company models gross margin to return above 50% in 2025.

Total selling, general, and administrative ("SG&A") expenses in the quarter were $10.6 million, a 43% improvement from $18.6 million in Q4 2023. Stringent expense controls were implemented during the year to better align with current revenue levels.

Net loss for the fourth quarter of 2024 was $3.4 million, or ($0.02) per share basic and diluted, compared to a net loss of $8.5 million, or ($0.06) per share basic and diluted, for the fourth quarter of 2023.

Excluding depreciation, amortization and other non-cash items, Charlotte's Web reported positive Adjusted EBITDA1 for the fourth quarter of 2024 of $0.3 million, a $6.8 million improvement compared to negative Adjusted EBITDA of $6.5 million in the fourth quarter of 2023.

Fiscal Year 2024 Financial Review
On a year-over-year basis, consolidated net revenue for the twelve months ended December 31, 2024, was $49.7 million, a decrease of 21.4% from $63.2 million in 2023. Revenue was negatively impacted by inflationary impacts on consumer spending and reduced retailer shelf allocations to the CBD category. The Company adopted a new e-commerce platform mid-year that has resulted in improving marketing, customer management, and sales volumes.

Gross profit for the year ended December 31, 2024, was $21.3 million, compared to $35.6 million for the year ended December 31, 2023. Gross profit was negatively impacted by a $4.1 million increase in inventory provision for 2024 due to the revaluation of aged hemp based on current market conditions. The increase was partially offset by lower inventory expenses and other variable costs associated with lower revenue in 2024. Gross profit before inventory provision was $25.4 million, or 51.1%, and $36.6 million, or 58.0%, in 2024 and 2023, respectively.

Total SG&A expense for 2024 was $53.3 million, compared to $75.6 million in the prior year. The $22.4 million or 29.6% decrease resulted from multiple actions taken in 2024 to reduce operating expenses and better align SG&A against the lower revenue levels, including workforce and insurance program adjustments, contract reviews and negotiations, and software optimizations. Additionally, in 2024, the Company amended its MLB Promotional Rights Agreement, resulting in a decrease in amortization and media expense related to MLB assets of approximately $4.9 million compared to 2023.

An operating loss of $32 million in 2024 improved 21.2% from an operating loss of $40.6 million in 2023. Net loss for 2024 was $29.8 million, or $(0.19) per share, basic and diluted, compared to a net loss of $23.8 million, or $(0.16) per share, basic and diluted, in 2023. The lower net loss in 2023 was due to a combined net gain of $20.0 million in that year in the fair value of the Company's debt derivative and from its investment in DeFloria.

Excluding depreciation, amortization, and interest, the EBITDA1 loss for 2024 was $17.6 million, as compared to an EBITDA loss of $6.3 million for 2023. 2024 included a higher inventory provision than 2023, which included the combined net gain of $20.0 million in fair value of the Company's debt derivative and from its investment in DeFloria. Excluding these items, the Adjusted EBITDA1 loss was $12.6 million for 2024, as compared to the Adjusted EBITDA loss of $22.7 million for 2023.

Balance Sheet and Cash Flow
Net cash used for operations in the fourth quarter of 2024 was $1.8 million. Net cash used for operations in the year ended December 31, 2024, was $21.2 million, including cash paid to MLB for license and media rights assets of $5 million. Capital expenditures of $3.9 million were primarily used for the in-house production of topical and gummy projects.

The Company's cash and working capital as of December 31, 2024, were $22.6 million and $31.1 million, respectively, compared to $47.8 million and $54.5 million as of December 31, 2023, respectively.

"With reduced cash burn, having cash reserves exceeding $22 million provides the runway for 2025 growth and beyond," said Mrs. Lind. "In-house production will increase in 2025, and continued expense discipline is key to stabilizing our financial position."

Consolidated Financial Statements and Management's Discussion and Analysis
The Company's audited consolidated financial statements and accompanying notes for the three and twelve-month periods ended December 31, 2024, and 2023, and related management's discussion and analysis of financial condition and results of operations ("MD&A"), are reported in the Company's 10-K filing on the Securities and Exchange Commission website at www.sec.gov and on SEDAR+ at www.sedarplus.ca and will be available on the Investor Relations section of the Company's website at https://investors.charlottesweb.com.

[Wolf-man jack]

Item 2.02 Results of Operations and Financial Condition.
On March 19, 2025, Charlotte’s Web Holdings, Inc. (the “Company”) issued an earnings release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the earnings release is furnished herewith as Exhibit 99.1 and incorporated in this Item 2.02 by reference.

[Wolf-man jack]

https://www.sec.gov/Archives/edgar/data/1750155/000175015525000006/0001750155-25-000006-index.htm

[Wolf-man jack]

https://www.sec.gov/Archives/edgar/data/1750155/000127956925000278/0001279569-25-000278-index.htm

[Wolf-man jack]

https://finance.yahoo.com/news/charlottes-reports-2024-fourth-quarter-110700259.html

[DarthYoda]

I found some YouTube videos from Ajna Biosciences and Charlotte's Web about DeFloria. The first one is from this week. The rest are older but contain much more info...
"DeFloria: A Novel Treatment Option for Autism Spectrum Disorder":
Mar 10, 2025

"Fireside Chat with AJNA's Scientific Advisory Board Members":
July 25, 2024

"AJNA WeFunder Investor Q&A Webinar:
Jul 3, 2024

[ap17]

.08 CENTS!! my apologies for missing it by 2 cents. My call was .10 2+ years ago. Told ya, never marry a stock especially a POS like this.

[Fangster]

Good stuff Yoda!   I wonder who the thumbs downer could be? 

[DarthYoda]

New article on DeFloria today..."Rising High: Exclusive talk with botanical drug JV DeFloria":
Mar. 13, 2025
https://markets.businessinsider.com/news/stocks/rising-high-exclusive-talk-with-botanical-drug-jv-defloria-1034475275

[DarthYoda]

$CWBHF+$TLRY= "Strategic Partners" in Canada...
"Health Canada Consults on Pathway for Health Products Containing CBD":
March 10, 2025

Health Canada recently announced that it is exploring a regulatory pathway that would allow products containing cannabidiol (“CBD”) to be purchased without a prescription.

https://www.jdsupra.com/legalnews/health-canada-consults-on-pathway-for-2521248/
"Tilray Brands Launches Charlotte’s Web™ CBD Gummies in Canada":
October 7, 2024
https://finance.yahoo.com/news/tilray-brands-launches-charlotte-cbd-110000280.html
"Tilray Brands and Charlotte’s Web Announce Strategic Alliance in Canada":
November 2, 2022
https://finance.yahoo.com/news/tilray-brands-charlotte-announce-strategic-110000543.html
"Charlotte's Web Secures Health Canada Approval to Bring its Proprietary CBD Cultivars to Canada":
Apr 20, 2021
https://www.prnewswire.com/news-releases/charlottes-web-secures-health-canada-approval-to-bring-its-proprietary-cbd-cultivars-to-canada-301271822.html
Charlotte's Web has FIVE CANADIAN PATENTED Hemp Cultivars...

# Patent # Patent Title Score
1. 3157865 HEMP PLANT NAMED 'EM15B2A170'
2. 3155121 HEMP PLANT NAMED 'AF14B15-21'
3. 3169446 HEMP PLANT NAMED 'KIRSCHE'
4. 3169404 HEMP PLANT NAMED 'LINDOREA'
5. 3101952 HEMP PLANT NAMED 'CW1AS1'

https://cipo.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=charlotte%27s+web&start=1&newSearch=0&type=basic_search

[DarthYoda]

Oh Canada!..."Health Canada has released a new consultation document looking at the potential regulatory path for CBD to be regulated as a natural health product. Feedback must be submitted by June 5, 2025."
March 7, 2025
https://stratcann.com/news/health-canada-seeks-more-feedback-on-cbd-as-a-natural-health-product-and-cbd-for-pets/
"Towards a pathway for health products containing cannabidiol: Natural health products containing cannabidiol":
https://www.canada.ca/en/health-canada/programs/consultation-towards-pathway-products-containing-cannabidiol/natural-health-products.html
"Towards a pathway for health products containing cannabidiol: Veterinary drugs containing cannabidiol for animal use":
https://www.canada.ca/en/health-canada/programs/consultation-towards-pathway-products-containing-cannabidiol/veterinary-drugs-animal-use.html
And a reminder..."FDA Solicits Public Comments on Use of Cannabis-Derived Products in Veterinary Medicine":
January 15, 2025

The comment period for this RFI opens on January 16, and will be open for 90 days, ending on April 16, 2025.

https://www.fda.gov/animal-veterinary/cvm-updates/fda-solicits-public-comments-use-cannabis-derived-products-veterinary-medicine
https://www.federalregister.gov/documents/2025/01/16/2025-00945/use-of-cannabis-derived-products-including-cannabidiol-in-veterinary-practice-request-for

[DarthYoda]

Here are some excerpts from an interesting new article...
"How the FDA lets chemicals pour into America’s food supply":
March 7, 2025

There are at least 950 substances in our food that are not permitted in Europe, according to one expert’s estimate, and chemicals linked to health concerns show up in hundreds of products that line the shelves of American supermarkets.

The FDA website lists 19 post-market determinations since 2010 that substances were not “generally recognized as safe.” Four involve chemical constituents of one mushroom and the mushroom itself. Others include an anabolic steroid, caffeinated alcoholic beverages, cannabidiol (CBD), Ginkgo biloba, melatonin, and partially hydrogenated oils.

Meanwhile, trichloroethylene, banned by the Environmental Protection Agency in December as “an extremely toxic chemical known to cause liver cancer, kidney cancer, and non-Hodgkin’s lymphoma,” is still allowed under FDA rules for use as a solvent in the production of foods.

FDA spokesperson Enrico Dinges said the agency will work with new leadership at HHS “to safeguard the food supply through pre-market and post-market safety evaluations of chemicals in the food supply.

More than a decade ago, Pew Charitable Trusts estimated that there were about 10,000 additives allowed in food in the United States — and that the FDA had not reviewed the safety of about 3,000 of them.

KFF Health News asked nine of the largest food manufacturers — The Coca-Cola Co., Conagra Brands, General Mills, Kellanova (successor to Kellogg), The Kraft Heinz Co., Mondelez International, Nestlé, PepsiCo, and Unilever — for the number of ingredients, if any, that go unnamed on their product labels and the names of those ingredients deemed safe without involvement by the FDA, and substances used in their products in the United States but not in Europe, and vice versa.
None provided answers to those questions.

For advice on whether ingredients are GRAS, companies may convene panels of specialists. The FDA has noted that panel members could be paid by the companies commissioning the review, but, in guidance to industry, it says “such compensation is not itself an unacceptable conflict."

https://www.cbsnews.com/news/fda-chemicals-food-supply/

[DarthYoda]

Could be boom time soon. Check this stuff out...The guy nominated to be the new head of the FDA is Dr. Marty Makary. The news has kinda painted him as anti-cannabis so far. However...he has also publicly acknowledged the therapeutic properties of cannabis. So...for starters here is a quote I found from him in a book review on Amazon...
"The CBD Skincare Solution: The Power of Cannabidiol for Healthy Skin":

"An eye-opening book about how the anti-inflammatory effects of CBD can play an important role in skin health and in improving lives."Marty Makary, MD, John Hopkins physician and New York Times bestselling author of The Price We Pay

https://www.amazon.com/CBD-Skincare-Solution-Cannabidiol-Healthy/dp/0738764884
Next, check this out..."How will Trump Nominations Impact the Dietary Supplement Industry?":
"Industry thought leaders discussed the prospect of Robert F. Kennedy, Jr. at the helm of HHS and Dr. Marty Makary in charge of FDA."
January 6, 2025

“FDA promised that they’re going to answer our citizen petition by July … if you have people in charge who are thinking about a much more holistic approach, they’re much more likely to balance the pharmaceutical industry’s interest and the supplement industry’s interest in a way that we think the law was intended,” Mister said. “The previous administration sat on the CBD issue for over 5 years, and didn’t do anything except conclude that they can’t regulate it,” concurred Israelsen.

https://www.nutraceuticalsworld.com/exclusives/how-will-trump-nominations-impact-the-dietary-supplement-industry/
Here is the petition...
"CRN Petitions FDA to Change Course on ‘Drug Preclusion’":
May 10, 2023

CRN asked for clearer and more consistent application of the statute which prohibits ingredients from dietary supplements due to past drug research.

https://www.nutraceuticalsworld.com/breaking-news/crn-requests-fda-to-change-course-on-drug-preclusion/
https://www.crnusa.org/sites/default/files/pdfs/comments-pdfs/CRN-CitizenPetition-FDA-DrugPreclusion050923.pdf
Going forward, the hearing to confirm Dr. Makary as head of the FDA is Thursday March 6 at 10:00am:

Hearings to examine the nomination of Martin Makary, of Virginia, to be Commissioner of Food and Drugs, Department of Health and Human Services. Thursday, Mar 06, 2025 10:00 AM

https://www.senate.gov/committees/hearings_meetings.htm

[Fangster]

Agree💯!  Ajna does have plans to do a transaction at some point and this is a direct comment made to me by people entrenched in all this.  Aside from the JV with CW, (IF) Defloria pans out, who do you think has first call on the fulfillment side for AJA 001?  Out year issue but very compelling nonetheless.   

I realize most disagree and I understand why but CW has enormous potential that goes beyond Defloria. 

 JMHO 😎

[DarthYoda]

Good to hear. Yes, DeFloria is interesting. I should have said Ajna or DeFloria instead of CW when I mentioned Jazz looking for acquisitions. CW is just in on the joint venture. Fwiw though, Orrin Devinsky is the same Lead Scientist behind the development of both Epidiolex and DeFloria(AJA001). I see Ajna and DeFloria have new 2025 investor decks posted. They're very detailed. The psychedelics look interesting too. CW still has the 2024 investor deck posted, but maybe we'll see a new one after the next report which I think may show CW's newer supplements selling well. Maybe one day Ajna will have an IPO and CW holders can have some shares for our long term support...
Ajna
https://ajnabiosciences.com/wp-content/uploads/2025/02/Investor_Deck_2025_Public_PDF_web.pdf
DeFloria
https://foundersuite.com/public_pitch_decks/0b0d6e7a-bfa5-4f27-a77c-9bdfb57a673b
CW
https://s22.q4cdn.com/636117063/files/doc_presentations/2024/Jun/28/cweb-2024-investor-presentation.pdf

[Fangster]

Good to see epidiolex doing well.   I know someone who takes it.  Very effective in this case and very expensive.  

Difloria is extremely interesting and think they're on to something very good. 

[DarthYoda]

I see Jazz Pharma just reported Q4, and Epidiolex is doing very well. Maybe that can be some kind of benchmark for what to expect from AJA001 one day. It's a testament to the effectiveness of CBD...

Epidiolex Net Product Sales: $275 million in Q4 2024, $972 million for the full year, up 15% year-over-year.

https://finance.yahoo.com/news/jazz-pharmaceuticals-plc-jazz-q4-071434447.html
Or...maybe Jazz would acquire CWBHF?...
"Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up Epidiolex patent fights: execs":
Feb 26, 2025

Epidiolex, currently the only FDA-approved CBD product to treat certain types of seizures, is expected to reach blockbuster status this year after its sales grew by 15% to $972 million in 2024.

https://www.fiercepharma.com/pharma/jazz-active-and-looking-ma-various-sizes-it-wraps-epidiolex-patent-fight

[Fangster]

Good stuff Yoda!   I realize drfloria entering P2  means plenty left to do but IMO this is a major milestone and good things will follow.  

Great to see the continued positive research being done around hemp and CBD.  

I've been taking CBD for 10 years.  There's no  comparable chemical based concoction on the market.  Natural wellness products are gaining serious traction.  The better CBD players will thrive but the question is who makes it to the other side!  

[Wolf-man jack]

“Charlotte's Web" or the "Company") will report its 2024 fourth quarter and year-end results prior to market open on March 19, 2025.“

https://finance.yahoo.com/news/charlottes-2024-fourth-quarter-earnings-182700022.html

[DarthYoda]

Lots of different stuff below...

"DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)":
Feb 24, 2025
https://www.prnewswire.com/news-releases/defloria-receives-investigational-new-drug-application-clearance-from-fda-for-phase-2-clinical-trial-of-aja001-an-oral-cannabinoid-drug-being-developed-for-the-treatment-of-autism-spectrum-disorder-asd-302382573.html

"With RFK Jr. in charge, supplement makers see chance to cash in":
2/21/2025

Last fall, before being named the senior U.S. health official, Robert F. Kennedy Jr. said the Trump administration would liberate Americans from the FDA's "aggressive suppression" of vitamins, dietary supplements, and other substances — ending the federal agency's "war on public health," as he put it.

With Kennedy now in the driver's seat, the industry will likely expect more: It aims to make bolder health claims for its products and even get the government, private insurers, and flexible spending accounts to pay for supplements, essentially putting them on an equal footing with FDA-approved pharmaceuticals.

On Feb. 13, the day Kennedy was sworn in as secretary of Health and Human Services, President Donald Trump issued a "Make America Healthy Again" agenda targeting alleged corruption in health regulatory agencies and instructing them to "ensure the availability of expanded treatment options and the flexibility for health insurance coverage to provide benefits that support beneficial lifestyle changes and disease prevention."
Kennedy has said exercise, dietary supplements, and nutrition, rather than pharmaceutical products, are key to good health. Supplement makers want consumers to be able to use programs like health savings accounts, Medicare, and even benefits from the Supplemental Nutrition Assistance Program, or SNAP, to pay for such items as vitamins, fish oil, protein powders, and probiotics.

The Alliance for Natural Health hopes that in lieu of strict FDA standards, Kennedy will enable companies to make expanded marketing claims based on evidence from non-FDA sources, Verkerk said, such as the National Institutes of Health's nutritional information site, which describes the pros and cons of different supplements.

https://www.msn.com/en-us/health/other/with-rfk-jr-in-charge-supplement-makers-see-chance-to-cash-in/ar-AA1zvjw7

"Possibilities of energy utilization of CBD extraction by-product":
17 February, 2023

During the last decade, the global pharmaceutical industry was primarily focused on cannabinoid extraction (mostly cannabidiol – CBD) from dry hemp (Cannabis sativa L.) biomass. Depending on the extraction method used, the first raw cannabinoid extract amounts to an average of under 10 % of total biomass. The remaining share of 90 % is waste. The aim of this research was to determine the usability of industrial hemp waste after the ultrasound extraction in ethanol for energy production via direct combustion and pyrolysis. The biomass of industrial hemp, variety Fortuna, was used in the research. Analyses were carried out by using standard methods for determining the content of proximate and ultimate analyses, Ash content was found to be 15,40 %, coke content was 22,12 %, fixed carbon was 8,12 %, whereas volatile substances were found to be 68,81 %. The obtained HHV was 16,60 MJ kg-1, while LHV was 15,35 MJ kg-1. After the pyrolysis process, the share of produced biochar (50.45 %) and bio-oil (13.70 %) was determined. The composition of biochar was analyzed using the standard methods – moisture content of 2.71 %, ash 29.22 %, and coke 37.06 %. The obtained results confirmed the potential of CBD extraction by-products in terms of high energy value and environmentally friendly raw materials for energy production. It has proven to be an attractive source of energy that has the potential to partially replace raw materials of fossil origin in energy production.

https://www.croris.hr/crosbi/publikacija/prilog-skup/830682

"Understanding Voluntary Carbon Markets and Hemp’s Potential for Change":
December 16, 2024

How It Works
1.Credits Are Generated: Projects like reforestation, renewable energy development, and sustainable regenerative farming techniques create carbon credits by eliminating or avoiding emissions.
2.Credits Are Verified: To ensure the project’s credibility, verification bodies confirm that the claimed reductions are real, measurable, and longterm.
3.Credits Are Traded: Buyers, typically companies looking to offset their emissions, purchase the credits, supporting the funding of these projects.

Challenges in the Current System
1.Complex Verification: Proving the effectiveness of carbon-reduction projects often requires sophisticated monitoring systems, making entry daunting for smaller participants.
2.High Costs: Smaller players, including smallholder farmers or grassroots projects, struggle with the financial burden involved in generating and navigating carbon credits.
3.Transparency Issues: Some markets lack clarity on where funds go and how environmental benefits are quantified, raising concerns about accountability.

Why Hemp? Why Now?
Hemp has long been praised for its environmental benefits, but its potential as a powerful carbon-sequestration crop is only beginning to be realized. Unlike many other crops, industrial hemp not only removes CO2 but also regenerates the soil, making it an ideal candidate for nature-based carbon credits.

Hemp’s Unique Advantages
1.Rapid Growth: Industrial hemp is one of the fastest-growing plants, capable of absorbing significant quantities of CO2 during its short growth cycle.
2.Versatile Applications: Beyond its environmental benefits, hemp can be used to produce textiles, construction materials, biochar, and more, creating additional economic opportunities.
3.Sustainability: Unlike some carbon-offset solutions, hemp farming leaves the land enriched, making it a regenerative approach to climate action.

https://hempcarbonstandard.org/understanding-voluntary-carbon-markets-and-hemps-potential-for-change/

[DarthYoda]

"Cannabidiol reshapes the gut microbiome to promote endurance exercise in mice":
18 February 2025

Abstract
Cannabidiol (CBD), a nonpsychoactive compound from Cannabis, has various bioactive functions in humans and animals. Evidence suggests that CBD promotes muscle injury recovery in athletes, but whether and how CBD improves endurance performance remains unclear. Here we investigated the effects of CBD treatment on exercise performance in mice and assessed whether this effect involves the gut microbiome. CBD administration significantly increased treadmill running performance in mice, accompanied by an increase in oxidative myofiber composition. CBD also increased mitochondrial biogenesis and the expression of associated genes such as PGC-1a, phosphorylated CREB and AMPK in muscle tissue. Interestingly, CBD altered the composition of the gut microbiome, and antibiotic treatment reduced the muscle endurance-enhancing effects of CBD and mitochondrial biogenesis. We isolated Bifidobacterium animalis, a microbe increased by CBD administration, and named it KBP-1. Treatment with B. animalis KBP-1 in mice resulted in improved running performance. Whole-genome analysis revealed that B. animalis KBP-1 presented high expression of genes involved in branched-chain amino acid biosynthesis, expression of branched-chain amino acid release pumps and metabolism of lactic acid. In summary, our study identified CBD and B. animalis KBP-1 as potential endurance exercise-promoting agents.

https://www.nature.com/articles/s12276-025-01404-5

[DarthYoda]

"Nanoemulsions with cannabidiol reduced autistic-like behaviors and reversed decreased hippocampus viable cells and cerebral cortex neuronal death in a prenatal valproic acid rat model":
07 Feb 2025

Prenatal exposure to VPA increased anxiety and grooming time, and reduced exploratory activity, sociability, and the social preference index in the animals. Furthermore, VPA-exposed animals exhibited elevated neuronal death and a reduction in viable cells in the hippocampus. In conclusion, CBD nanoemulsion treatment reversed autistic-like behaviors, potentially by protecting against hippocampal neuronal death.

https://www.scielo.br/j/aabc/a/jkp56mWRhknfsvMytM7qzWc/?lang=en

[DarthYoda]

You can induce Alzheimer's Disease in Rats by injecting them with Aluminum. You can protect them from the Aluminum, and thus the Alzheimer's as well, with Cannabis Oil...
"The therapeutic effect of the oily extract of Cannabis sp. in Aluminum Chloride-Induced Alzheimer's Disease in Rats":
May 14, 2024

Results: Reduction of more than 80% in cell death in the dentate gyrus region of the hippocampus in animals treated with cannabis extract. Furthermore, a reduction in total protein levels by approximately 20% and an increase (15%) in antioxidant enzymes in relation to the positive control were also observed in the serum. Conclusion: The use of the oily extract of Cannabis sp. in a 2:1 ratio of delta-9-tetrahydrocannabinol (THC): Cannabidiol (CBD) effectively reduced hippocampal neuron deaths from amyloidosis induced in chronic aluminum chloride intoxication.

https://acervomais.com.br/index.php/saude/article/view/14270
"Cannabis sativa-based oils against aluminum-induced neurotoxicity":
17 June 2023

We concluded that the oils have a protective effect and might be used with proposals for neurological and antioxidant impairment avoidance caused by Al intoxications.

https://www.nature.com/articles/s41598-023-36966-9
"A high-fat meal significantly impacts the bioavailability and biphasic absorption of cannabidiol (CBD) from a CBD-rich extract in men and women":
29 January 2025

Using a randomized crossover design, the study evaluated the impact of a standardized high-fat meal compared to fasting on the oral bioavailability of CBD. Consumption of a high-fat meal significantly increases the bioavailability of CBD.

https://www.nature.com/articles/s41598-025-87621-4

[DarthYoda]

CW is tariff-proof. Their Canadian products are made with Canadian grown hemp and their American products are made with American grown hemp. Both use their patented hemp genetics...

At the end of the third quarter, Charlotte's Web gummies were launched in Canada. These gummies are crafted using Charlotte's Web's proprietary hemp genetics, cultivated in the pristine northern Okanagan Valley of British Columbia, Canada, and feature full-spectrum CBD hemp extract combined with functional botanical supplements, designed to provide synergistic support for targeted wellness benefits. The gummies are produced in accordance with Health Canada Processing and under a license by Aphria Inc., a subsidiary of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY). They are being distributed through cannabis retailers in select provinces and on the Tilray Medical website. The launch of gummies follows the earlier availability of Charlotte's Web hemp extract oil tinctures and topicals in Canada, expanding Canadian access to trusted, high-quality CBD products.

https://investors.charlottesweb.com/press-releases/press-release-details/2024/Charlottes-Web-Reports-2024-Third-quarter-Financial-Results/default.aspx
https://investors.charlottesweb.com/press-releases/press-release-details/2024/Tilray-Brands-Launches-Charlottes-Web-CBD-Gummies-in-Canada-2024-He66wHbdNS/default.aspx
"Charlotte’s Web Announces First International Harvest with Patented Hemp Cultivars in Canada":
November 11, 2021
https://www.newcannabisventures.com/charlottes-web-announces-first-international-harvest-with-patented-hemp-cultivars-in-canada/

[DarthYoda]

"New Peer-reviewed Study Again Confirms Childhood Vaccines Are Likely Responsible for Nearly 80% of the Autism Cases in US":
29 January 2025
https://www.globalresearch.ca/childhood-vaccines-responsible-80-autism-cases-us/5878382
Here is the actual study of 47,155 children...
"Vaccination and Neurodevelopmental Disorders: A Study of Nine-Year-Old Children Enrolled in Medicaid":
01/23/2025

Children with just one vaccination visit were 1.7 times more likely to have been diagnosed with ASD than the unvaccinated (95% CI: 1.21, 2.35) whereas those with 11 or more visits were 4.4 times more likely to have been diagnosed with ASD than those with no visit for vaccination (95% CI: 2.85, 6.84).

https://publichealthpolicyjournal.com/vaccination-and-neurodevelopmental-disorders-a-study-of-nine-year-old-children-enrolled-in-medicaid/

SEN. MULLIN: "1-in-36. If that's not a pandemic, then what is? It used to be 1-in-10,000 have autism. Can any of you guys with a straight face say that we shouldn't look at every aspect to what we're putting in our kids, be it from the food to the vaccines?"

SEN. MULLIN: "1-in-36. If that's not a pandemic, then what is? It used to be 1-in-10,000 have autism. Can any of you guys with a straight face say that we shouldn't look at every aspect to what we're putting in our kids, be it from the food to the vaccines?" pic.twitter.com/lzgGQF9IlQ

— Chief Nerd (@TheChiefNerd) January 30, 2025

LoL@ these people..."Yes, Some Vaccines Contain Aluminum. That’s a Good Thing.
R.F.K. Jr. and others have blamed the ingredient for allergies and other illnesses. Scientists say it actually bolsters the immune response."
Jan. 24, 2025
https://www.nytimes.com/2025/01/24/health/aluminum-vaccines-kennedy.html